Phase II Trial of Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2014
At a glance
- Drugs Bortezomib (Primary) ; Ofatumumab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Biomarker; Therapeutic Use
- 07 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 20 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Mar 2012 New source identified and integrated (Oregon Health and Science University Institutional Review Board record, IRB00007042).